Tokyo, Japan – 8 November 2017: Sosei Group Corporation (‘Sosei’; TSE Mothers Index 4565), is pleased to note that our strategic minority investment company MiNA Therapeutics ('MiNA') has announced a collaboration and licensing agreement with the global pharmaceutical company Boehringer Ingelheim for the development of novel treatment approaches for fibrotic liver diseases.
Under the terms of the agreement, MiNA will receive an upfront payment and committed research funding as well as potential research, development and regulatory milestone payments totaling up to EUR 307 million. In addition, MiNA is entitled to double-digit royalties on sales of selected products resulting from the partnership. No further financial details were disclosed.
Commenting on the release, Peter Bains, CEO at Sosei, said: “We are very encouraged by this agreement, which is MiNA’s first ever major collaboration and reinforces its leading position in small activating RNA (‘saRNA’) therapeutics. Furthermore, we believe it represents a strong validation of the broad potential for its proprietary technology.”